On December 18, 2023, Neurogene Inc. closed the transaction. The company has now issued 36,934,089 common shares and 23,964,846 pre-funded warrants for gross proceeds of approximately $95 million. At the closing, the securities were converted into shares of company's common Stock and $0.000001 pre-funded warrants at a rate of 0.0756 shares of common stock per share, and 0.0756 $0.000001 pre-funded warrants for each company's prefunded warrant.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.35 USD | -1.40% | +0.32% | +92.72% |
Jun. 03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
Jun. 03 | Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
766.2 USD | -0.33% | -1.44% | 114B | ||
37.35 USD | -1.40% | +0.32% | 485M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+92.72% | 485M | |
+49.41% | 56.95B | |
+40.40% | 40.26B | |
-6.72% | 39.32B | |
-5.96% | 28.37B | |
+12.99% | 26.45B | |
-19.82% | 19.41B | |
+32.35% | 12.54B | |
-0.08% | 12.15B | |
+25.18% | 12.21B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Neurogene Inc. announced that it has received $95 million in funding from a group of investors